Stockreport

Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update

Ocuphire Pharma, Inc.  (OCUP) 
PDF On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol® Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial D [Read more]